| Name | Danirixin |
|---|---|
| Synonyms |
Urea, N-[4-chloro-2-hydroxy-3-[(3S)-3-piperidinylsulfonyl]phenyl]-N'-(3-fluoro-2-methylphenyl)-
1-{4-Chloro-2-hydroxy-3-[(3S)-3-piperidinylsulfonyl]phenyl}-3-(3-fluoro-2-methylphenyl)urea Danirixin GSK1325756 |
| Description | Danirixin is a selective, and reversible CXCR2 antagonist, with IC50 of 12.5 nM for CXCL8. |
|---|---|
| Related Catalog | |
| Target |
CXCL8-CXCR2:12.5 nM (IC50) |
| In Vitro | Danirixin is a small molecule, CXCR2 antagonist being evaluated as a potential anti-inflammatory medicine[1]. |
| References |
| Density | 1.5±0.1 g/cm3 |
|---|---|
| Boiling Point | 533.1±50.0 °C at 760 mmHg |
| Molecular Formula | C19H21ClFN3O4S |
| Molecular Weight | 441.904 |
| Flash Point | 276.2±30.1 °C |
| Exact Mass | 441.092529 |
| LogP | 3.93 |
| Vapour Pressure | 0.0±1.5 mmHg at 25°C |
| Index of Refraction | 1.638 |
| Storage condition | 2-8℃ |